Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 166-181 http://medscipublisher.com/index.php/cge 173 al., 2019). Furthermore, the lack of targeted therapies for TNBC underscores the need for continued research into the molecular underpinnings of this subtype to identify novel therapeutic targets and improve patient outcomes. In summary, the genetic heterogeneity and subtype specificity of breast cancer significantly influence the pathogenesis, prognosis, and treatment strategies for each subtype. Understanding these genetic features is crucial for developing personalized treatment approaches and improving clinical outcomes for breast cancer patients. 6 Genomic Technologies and Their Impact on Breast Cancer Research 6.1 Next-Generation sequencing (NGS) Next-Generation Sequencing (NGS) has revolutionized the field of genomics, providing unprecedented insights into the genetic underpinnings of breast cancer. NGS allows for the rapid sequencing of millions of DNA fragments simultaneously, offering a comprehensive view of the genome. This technology has been instrumental in identifying novel genetic mutations associated with breast cancer, which were previously undetectable with traditional sequencing methods. NGS has enabled the discovery of new driver and passenger mutations, rare chromosomal rearrangements, and other genomic aberrations in breast cancer. For instance, whole genome and exome sequencing have revealed the complex genomic architecture of breast cancer, identifying mutations in genes such as TP53, PIK3CA, and BRCA2, among others (Wheler et al., 2013; Verigos and Magklara, 2015). These findings have significant implications for understanding the molecular mechanisms driving breast cancer and for developing targeted therapies. Moreover, NGS has facilitated the identification of unique genomic profiles in breast cancer patients, which can be correlated with their response to targeted therapies. For example, a study involving 57 patients with advanced or metastatic breast cancer demonstrated that NGS profiling could identify specific molecular aberrations that were prognostic and predictive of treatment response (Wheler et al., 2013). This highlights the potential of NGS to personalize breast cancer treatment, improving patient outcomes. 6.2 CRISPR-Cas9 and gene editing The advent of CRISPR-Cas9 technology has opened new avenues for gene editing in breast cancer research. CRISPR-Cas9 allows for precise modifications of the genome, enabling researchers to investigate the functional roles of specific genes in breast cancer development and progression. This technology holds great promise for identifying new therapeutic targets and for developing gene-based therapies. One of the significant potentials of CRISPR-Cas9 in breast cancer research is its ability to create knockout models to study the effects of gene loss-of-function. This can help in understanding the role of tumor suppressor genes and identifying potential vulnerabilities in cancer cells. Additionally, CRISPR-Cas9 can be used to introduce specific mutations into the genome, mimicking the genetic alterations observed in breast cancer patients. This can provide valuable insights into the molecular mechanisms driving the disease and aid in the development of targeted therapies. However, the application of CRISPR-Cas9 in breast cancer research is not without challenges. One of the primary concerns is the off-target effects, where unintended genomic modifications can occur, potentially leading to undesirable consequences. Ensuring the specificity and efficiency of CRISPR-Cas9 is crucial for its safe and effective use in clinical settings. Additionally, the delivery of CRISPR-Cas9 components to target cells in vivo remains a significant hurdle, requiring the development of efficient and targeted delivery systems. 6.3 Liquid biopsies and genomic profiling Liquid biopsies have emerged as a promising non-invasive tool for monitoring genetic mutations and treatment response in breast cancer. This technique involves the analysis of circulating tumor DNA (ctDNA) in the blood, providing a real-time molecular profile of the tumor. Liquid biopsies offer several advantages over traditional tissue biopsies, including the ability to capture tumor heterogeneity and to monitor disease progression and treatment response dynamically.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==